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Summary
AIMS: Implementing the Chronic Care Model (CCM) via
involvement of specially trained practice nurses improves
cardiovascular risk profiles and perception of care among
type 2 diabetes patients in small primary care practices
(PCPs) in the short term. Little is known about the long-
term effects of this intervention.
METHODS: Cross-sectional survey among the partici-
pants of the cluster randomised controlled CARAT trial (30
PCPs, 303 diabetes patients), 3 years after its completion.
OUTCOMES: Proportion of patients still treated according
to the CCM, possible reasons for discontinuation, glyco-
sylated haemoglobin (HbA1c), blood pressure, low densi-
ty lipoprotein cholesterol, and accordance with CCM (as-
sessed by means of PACIC [Patient Assessment of
Chronic Illness Care]).
RESULTS: Overall, 40.9% of practices (40.7% of patients)
continued using the CCM. PCPs originally randomised to
the intervention group were significantly more likely to be
still using the CCM (11 PCPs / 88 patients vs 11 PCPs / 94
patients, p <0.001). Main reasons for discontinuation were
organisational (40.9%) and financial aspects (18.1%), and
the general practitioner refusing to transfer treatment re-
sponsibility (18.1%). HbA1c and PACIC development over
the long term showed significant positive effects in favour
of PCPs originally randomised to the intervention group
and practices continuing to treat patients according to the
CCM.
CONCLUSIONS: Diabetes care according to the CCM, in-
cluding the involvement of trained practice nurses, is a
reasonable tool to improve care in the long-term. CCM
training of the whole team is essential to overcome organ-
isational challenges. Continuous team education, techni-
cal decision support, and recognition of the importance of
these new structures in healthcare policy might improve
the long-term clinical effect of the team approach.
Clinical trial registration number: ISRCTN05947538.
Key words: chronic care model, diabetes care, general
practice, HbA1c, PACIC, practice nurse, primary care
Introduction
In most European countries, an increasing mismatch can
be observed between, on the one hand, rising numbers of
patients with chronic diseases [1] and, on the other hand,
a shortage of general practitioners, who are mainly respon-
sible for treating these patients [2]. In order to neverthe-
less enable complex health care and cope with rising costs,
team-based approaches have been developed for treatment
of the chronically ill. The cluster-randomised CARAT trial
(Chronic CARe for diAbeTes) [3–6] showed that imple-
menting the Chronic Care Model (CCM) in diabetes care
via involvement of specially trained practice nurses [7,
8] is feasible in small primary care practices (PCPs), im-
proves the cardiovascular risk profile and is perceived by
patients to be better structured care, at least on the short
term. Little is known on the long-term effects of such an
intervention.
The aim of this study was, therefore, to assess the feasibil-
ity and practicability of implementing the CCM in small
PCPs in the long term. We assessed the proportion of pa-
tients still treated according to CCM 3 years after comple-
tion of the CARAT trial, as well as reasons for discontin-
uing the use of the CCM, and the development of clinical
outcomes over time (glycosylated haemoglobin [HbA1c],
blood pressure, low density lipoprotein [LDL]-cholesterol
and compliance with CCM (assessed by use of Patient As-
sessment of Chronic Illness Care [PACIC]).
Materials and methods
Subjects, data collection and measurements
We performed a cross-sectional questionnaire survey
among the participants who completed the cluster-ran-
domised controlled CARAT trial [3–6], 3 years after its fi-
nalisation.
CARAT Trial
Detailed information about design and methods, baseline
characteristics and results of the trial have been published
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previously [3–6]. The eligibility criteria for the CARAT
trial were PCPs participating in routine primary care of un-
selected patients. The inclusion criteria for patients were
adulthood (age >18 years), diagnosis of type 2 diabetes ac-
cording to international diagnostic criteria [9] and at least
one HbA1c level of ≥7.0% measured within the preceding
year. Exclusion criteria were insufficient language skills
to read and understand informed consent, patient infor-
mation and the questionnaires, patients who contacted the
practice for emergencies only or as a substitute practice
(i.e., no continuous patient-doctor relationship), and a life
expectancy less than 6 months. Fifteen PCPs were ran-
domised to the intervention and 15 to the control group.
Recruitment of PCPs took place between November 2009
and February 2010. Recruitment of patients and baseline
assessments took place between January and April 2010
(T0). The intervention ran from April 2010 until May
2011, and follow-up assessments were conducted 1 year
after baseline assessments (T1). The intervention aimed at
providing team care according to the CCM by means of in-
volving a trained practice nurse in the care of diabetic pa-
tients. Therefore, practice nurses of the intervention group
were trained soon after randomisation in a 6-day educa-
tional course “Treatment of long term patients – module di-
abetes,” organised by the Union of Swiss Practice Nurses
[10]. The course provided medical knowledge about the
treatment of diabetes patients and general communication
skills, and it empowered practice nurses for their role in a
team providing structured care for chronically ill patients.
The practice nurses also learned how to perform visits and
follow-up consultations by means of a monitoring tool de-
veloped for the study [3]. In addition, PCPs and practice
nurses from the intervention group participated in two
4-hour interactive workshops. The first workshop took
place soon after randomisation and addressed the imple-
mentation of the team approach in practice and evidenced-
based therapy of diabetes. The second workshop took place
after 6 study months, and covered professional exchange
between practice nurses and PCPs regarding implemen-
tation experience and management of cardiovascular risk
factors. The intervention included practice nurses that were
involved in the care of type 2 diabetes patients. Practice
nurses planned independent consultations with patients.
The monitoring tool guided them through the consulta-
tions, and provided the opportunity to record relevant pa-
rameters and assistance for self-management support in or-
der to help the patient in selecting appropriate, concrete
behavioural goals, in developing plans for reaching those
goals, and in evaluating the progress and adequacy of those
plans. The monitoring tool addressed clinical parameters
(e.g., HbA1c, blood pressure and LDL-cholesterol levels),
examinations (e.g., food control, neurological tests and
eye examinations), adherence to prescribed drugs, self-care
goals, and other recommendations. The clinical aim of the
tool was to ensure that treatment recommendations were
followed. The assessed parameters were classified regard-
ing their clinical urgency and importance into a traffic light
scheme (green, amber, and red), and the practice nurses
forwarded the tool to the PCPs. Therefore, the PCPs ob-
tained an immediate overview on the current situation of
the patients. We recommended practice nurse consultations
every 4 months, but frequency could be adapted according
to the clinical situation of the patient.
The study protocol for the CARAT study was approved by
the ethics committee of the Kanton Zurich and received an
unrestricted positive vote on 25 January 2010 [4].
Current follow up
The current follow-up study among the 30 originally par-
ticipating PCPs of the CARAT trial (303 type 2 diabetes
patients) was performed in 2014, 3 years after the end of
the trial (T2). Recruitment of participants took place be-
tween April and October 2014. After completion of the
CARAT trial, the practice nurses of the control group were
given the opportunity to participate in the same diabetes
management course that the intervention group had partic-
ipated in. In contrast to the training of the CARAT inter-
vention group, no common workshops were provided for
the general practitioners. For the data analysis, we consid-
ered all the participating PCPs from the intervention group.
Since the focus of the current follow-up was to evaluate
the effect of implementing the CCM in the long term, only
PCPs from the original control group whose practice nurs-
es had completed the diabetes management course were in-
cluded. Thirteen of the 15 practice nurses of the control
group had participated in the course, two had not. Their da-
ta, including the associated 12 patients, could therefore not
be taken into consideration for the follow up evaluation.
The current follow up study included two types of ques-
tionnaire, one filled out by the practice team and one by the
patients (appendices 1 and 2). In the CARAT trial, PCPs
had created a list with the study participants and their cor-
responding code. According to this list, which remained at
the participating PCPs, the practices were able to recruit
the CARAT patients for the current follow-up. Both ques-
tionnaires were marked with this patient code and sent to
the University of Zurich in a stamped envelope indepen-
dently by the patients and practice teams. The university
had no access to the patients’ names; anonymity was there-
fore ensured.
The questionnaire filled out by the practice team (general
practitioner and/or practice nurse) consisted of a qualita-
tive and quantitative section. The qualitative section in-
cluded questions about the structure of care the PCP is
currently working with. The aim was to assess whether
patients are still treated according to the intention of the
CARAT study, meaning that the practice nurse is essen-
tially involved in the treatment of diabetic patients ac-
cording to the CCM. We also assessed whether the traffic
light scheme is used as a monitoring tool. The reasons
for a negative answer to these questions were assessed by
means of free text. The quantitative section included clin-
ical and laboratory follow-up parameters on the specific
study patient (within the previous 6 months). The prima-
ry and secondary outcomes of the original CARAT study
were analysed over a period of 4 years, meaning that we
compared the baseline data (T0 in 2010) with the current
findings (T2 in 2014), according to the original randomisa-
tion and the current modus operandi concerning CCM (fig.
1).
The questionnaires filled out by the patients consisted
mainly of the PACIC [11, 12], which aims at evaluating the
subjectively experienced compliance of medical care with
the CCM.
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Outcomes
The study outcomes were: proportion of patients still treat-
ed according to CCM, possible reasons for discontinuation,
development of clinical parameters between T0 and T2
(HbA1c, blood pressure, LDL-cholesterol, and compliance
with CCM [assessed with PACIC]).
Statistical methods
In order to systematically summarise and analyse the qual-
itative data concerning structure of care, we performed a
framework analysis [13]. Clinical data and PACIC were
analysed according to the intention to treat method (last
observation carried forward). Characteristics of PCPs and
patients are presented as means and standard deviations
(SDs) or confidence intervals (CIs) for continuous vari-
ables, and frequencies and percentages for categorical data.
After testing if the clinical data is well modelled by a nor-
mal distribution (Shapiro-Wilk test and distributional diag-
nostic plots), either parametric or nonparametric indepen-
dent comparison tests were used. For variables that were
not normally distributed, Wilcoxon rank sum tests were
used to compare the clinical outcomes between the differ-
ent groups. If the hypothesis that the sample comes from a
population that has a normal distribution was not rejected,
parametric tests were conducted. To compare difference
scores (T2 minus T0) and scores at T2 on clinical variables
between PCPs of the intervention- and control-group, as
well as between PCPs still using or not using the CCM,
two sample-independent Student t-tests were conducted.
The following parameters were not normally distributed:
HbA1c at T2, HbA1c T2−T0, systolic blood pressure at
T2, LDL-cholesterol at T2, LDL-cholesterol T2−T0. The
following parameters were normally distributed: systolic
blood pressure T2−T0, diastolic blood pressure at T2, dias-
tolic blood pressure T2−T0. For analysis of the change in
clinical parameters, the paired t-test, followed by a Wilcox-
on signed rank if not normally distributed, was performed.
A chi-square test of independence was used to examine
the relation between target levels and time (T0, T2) as
well as to examine the relation between initial randomi-
sation and CCM usage. The significance level was set at
0.05 (two sided). Statistical analyses were performed us-
ing SPSS (Version 22) and Stata (version 13.0, StataCorp,
2010).
Results
Study population
From the 30 PCPs and 326 type 2 diabetes patients orig-
inally participating in the CARAT trial, 30 PCPs and 303
patients completed the study. Baseline characteristics of
the CARAT patients are listed in table 1. For the current
follow up, 24 PCPs (80%) and 194 patients (64.0%) agreed
to participate. Six PCPs with 67 patients refused to partic-
ipate owing to time and personnel shortages. The detailed
study population and dropouts are listed in figure 2. All
practice nurses of the intervention group were trained in
implementing elements of CCM into practice during the
trial. In the control group, all practice nurses apart from
two were trained in the CCM after completion of the trial.
Characteristics of these two PCPs, including 12 patients,
could therefore not be taken into consideration for the cur-
rent follow up evaluation, leaving 22 PCPs (73.3%) with
182 patients (60.1%) for further analyses. Eleven (45.8%)
had been originally randomised to the intervention group
of the CARAT trial, and 13 (54.2%) to the control group
(fig. 2).
Practice organisation according to the CCM
Thirteen of the 22 PCPs (59.1%) did not treat 108 of
the 182 patients (59.3%) according to the CCM. The 11
PCPs originally randomised into the intervention group
Figure 1: Implementation of the Chronic Care Models over 4 years.CARAT = Chronic CARe for diabetes trial; n = number of primary care
practices; Pat = patients; CCM = Chronic Care Model
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were more likely to still treat their 88 patients according
to CCM than the 11 practices (94 patients) originally ran-
domised to the control group (chi-square 48.402, degrees
of freedom [DF] 192, p <0.001, fig. 1). The main reasons
for currently not using the CCM for the treatment of dia-
betic patients were personnel and organisational problems
(n = 9), mainly due to commonly occurring changes in the
employment structure of the practice nurses, the associat-
ed lack of capacity / missing resources and lacking accom-
modation. The second most common reason was financial
problems (n = 4), since the billing process of practice nurs-
es involved in patient treatment is not settled in the cur-
rent insurance structures, where only physicians’ work can
be billed. Additionally, general practitioners were not will-
ing to transfer treatment responsibility (n = 4) because of
the fear of losing control or of low workload, or patients
did not want to be treated according to the CCM (n = 4).
Lack of benefits combined with additional work and costs
were mentioned only once (multiple statements possible).
In general, PCPs treated their patients consistently, mean-
ing that all patients of the same PCP were treated accord-
ing to the CCM or not.
Table 1: Baseline patient characteristics and clinical measures.
Mean ± SD or n (%)
Age (years) 67.1 ± 10.6
Male gender 187 (57.4%)
Living together with partner/family 246 (78.3%)
Still working 100 (32.2%)
Education (years) 11.6 ± 3.2
Smoking status
Current smoker 36 (11.5%)
Former smoker 129 (41.1%)
Never smoker 149 (47.4%)
Duration of diabetes (years) 9.9 ± 7.6
Glycated haemoglobin (%) 7.7 ± 1.3
Self-monitoring of blood glucose
None 65 (19.9%)
Daily (≥1) 133 (40.8%)
Weekly (≥1) 101 (31.0%)
Monthly (≥1) 27 (8.3%)
Number of consultations last year 8.07 ± 6.0
Systolic blood pressure (mm Hg) 139.1 ± 17.6
Diastolic blood pressure (mm Hg) 80.9 ± 10.5
Pulse 73.7 ± 11.9
Body-mass index (kg/m2) 30.6 ± 5.6
Low-density lipoprotein-cholesterol 2.7 ± 1.1
Number of comorbidities 2.66 ± 1.6
Hypertension 231 (71.3%)
Hyperlipidaemia 208 (66.7%)
Obesity 173 (53.1%)
Coronary heart disease 66 (20.4%)
Depression 38 (11.7%)
Asthma / chronic obstructive pulmonary disease 32 (9.8%)
Heart failure 22 (6.8%)
Stroke 17 (5.2%)
Cancer 13 (4.2%)
Antidiabetic therapy 312 (96.6%)
None 12 (3.7%)
Only oral* 208 (64.4)
Only insulin* 26 (8.0)
Combined (insulin and oral)* 77 (23.8)
Any antihypertensive agent* 246 (76.2)
Any antiplatelet/anticoagulation therapy* 179 (55.4)
Any lipid-lowering therapy* 182 (56.3)
Any antidepressants* 37 (11.5)
Number of drugs total 4.8 (2.1)
PACIC summary score 3.18 ± 0.85
Patient activation 3.83 ± 1.13
Delivery system / practice design 3.87 ± 0.82
Goal setting / tailoring 2.86 ± 0.98
Problem solving / contextual 3.26 ± 1.22
Follow-up / coordination 2.66 ± 1.05
* More than one drug possible
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Traffic light scheme as monitoring tool
Two PCPs (9.1%, one originally intervention and one con-
trol group) with 11 patients (6%) still used the traffic light
scheme as a monitoring tool. The main reason for currently
not using the scheme was the utilisation of an alternative
tool (n = 12), mainly the use of an electronic patient record
with a linked diabetes monitoring system, a practice own
scheme, or cooperation with hospitals and their schemes.
Five PCPs stated that the scheme was confusing and com-
plex. Five PCPs stated it was pointless using it if the study
nurse was not involved in the treatment of patients. Three
PCPs did not know about the scheme (multiple statements
possible).
Clinical parameters
HbA1c
Overall, the absolute HbA1c did not change significantly
over 4 years (T0 mean 7.74%, SD 1.34% vs T2 mean
7.58%, SD 1.32%; DF 154, p = 0.249). By the time of
the current follow-up, no significant difference between
patients from the original intervention compared with the
control group was found (control mean 7.51%, SD1.49%
vs intervention mean 7.65%, SD 1.13%; DF 153, p =
0.092). There was a significant difference in the change in
HbA1c according to randomisation; the original interven-
tion group showed significantly lower changes in HbA1c
(intervention T2−T0 mean 0.43%, SD 1.85% vs control
T2−T0 mean 0.10%, SD 1.21%; DF 153, p = 0.04) (table
2). Additionally, a significant difference in HbA1c was de-
tected at the time of follow up, depending on whether the
PCP treated their patients according to the CCM or the
classical model: patients treated according to CCM dis-
played lower values (CCM T2 mean 7.40%, SD 1.33% vs
no CCM T2 mean 7.73%, SD 1.29%; DF 153, p = 0.025)
(table 3). The change of HbA1c according to implemen-
tation of the CCM showed a trend in favour of PCPs us-
ing the CCM (CCM T2−T0 mean −0.28%, SD 1.41% vs
no CCM T2−T0 mean −0.05%, SD 1.70%; DF 153, p =
0.071) (table 3). If the target for HbA1c levels was set at
7.5%, the target was reached significantly more often at the
time of the current follow up than at baseline (52 vs 26%,
chi-square 7.945, p = 0.005, data not shown). This find-
ing was independent of initial randomisation (44 vs 42%,
chi-square 0.351, p = 0.554) or current implementation of
the CCM as a treatment concept (44 vs 42%, chi-square
2.233, p = 0.135). If the target for HbA1c levels was set ac-
cording to the initial study protocol at <7% (based on the
guideline valid at that time) no significant improvement
over time could be found (15 vs 21%, chi-square 1.164, p
= 0.281). Practices initially randomised to the intervention
group (33 vs 20%, chi-square 5.642, p = 0.018) and prac-
tices still working with the CCM achieved this target level
significantly more often (32 vs 21%, chi-square 6.888, p =
0.009).
Blood pressure
Diastolic blood pressure was significantly lower at the cur-
rent follow-up compared with baseline measures (T0 mean
81.65, SD 10.17 mm Hg vs T2 mean 77.16, SD 9.27 mm
Hg; DF 155, p<0.001), whereas the systolic blood pres-
sure did not change significantly (table 2). These find-
ings, as well as achievement of target levels, were indepen-
dent of original randomisation or treatment concept (tables
2 and 3). Target level achievement rates did not change
when analysed with the updated or initial target levels of
Figure 2: Study population and drop-outs.CARAT = Chronic CARe for diabetes trial; n = number of primary care practices; x = number of pa-
tients; Pat = patients; CCM = Chronic Care Model; PCP = primary care practice
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<140/90 mm Hg or <130/80 mm Hg. respectively (data not
shown).
LDL-cholesterol
No significant difference in LDL-cholesterol levels was
found between practices still working with the CCM and
practices working with the traditional treatment concept,
as well as for randomisation to the original intervention
or control group (tables 2 and 3). If the target LDL-cho-
lesterol level was 2.6 mmol/l, it was reached significantly
more often at the follow-up than at baseline (59 vs 20%,
chi-square 16.985, p <0.001, data not shown), independent
of initial randomisation (39 vs 48%, chi-square 0.381, p =
0.537) or treatment according to CCM (41 vs 46%, chi-
square 0.293, p = 0.588).
Table 2: Changes in clinical parameters and PACIC according to randomisation to the initial intervention or control group.
T0
total popula-
tion
mean (SD)
T2
total popula-
tion
mean (SD)
Difference
T2−T0
total popula-
tion
mean (SD)
Difference
T2−T0 inter-
vention
mean (SD)
Difference
T2−T0
control
mean (SD)
(Difference T2−T0
intervention) − (Dif-
ference T2−T02
control)
mean (CI)
T2
intervention
mean (SD)
T2
control
mean (SD)
T2 interven-
tion – T2 con-
trol
mean (CI)
HbA1c (%)
n = 155
7.74
(1.34)
7.58
(1.32)
0.16
(1.57)
−0.43
(1.85)
0.10
(1.21)
−0.53*
(−1.02, −0.03)
7.51
(1.49)
7.65
(1.13)
−0.14
(−0.55, 0.27)
SBP (mm Hg)
n = 156
140.34
(17.91)
136.90
(17.83)
−3.44
(21.02)
−3.27
(22.45)
−3.60
(19.73)
0.34
(−6.33, 7.01)
138.36
(20.57)
135.54
(14.83)
2.82
(−2.82, 8.46)
DBP (mm Hg)
n = 156
81.65
(10.17)
77.16
(9.27)
−4.49*
(12.04)
−5.75
(12.80)
−3.33
(11.25)
−2.41
(−6.21, 1.39)
78.51
(8.93)
75.91
(9.45)
2.59
(−0.32, 5.51))
LDL (mmol/l)
n = 147
2.58
(1.09)
2.52
(0.99)
−0.06
(1.06)
−0.02
(1.10)
−0.12
(1.02)
0.14
(−0.21, 0.48)
2.69
(1.03)
2.37
(0.92)
0.32
(0.00, 0.63)†
PACIC Sum
n = 110
3.28
(0.83)
3.18
(0.88)
0.10
(0.76)
0.16
(0.72)
−0.27
(0.73)
0.43*
(0.15, 0.72)
3.32
(0.89)
3.12
(0.87)
0.19
(−0.13, 0.52)
PACIC pat. act.
n = 122
3.94
(1.05)
3.78
(1.05)
−0.17
(0.99)
−0.04
(1.03)
−0.25
(0.96)
0.21
(−0.16, 0.58)
3.76
(1.03)
3.76
(1.06)
−0.00
(−0.38, 0.38)
PACIC del. sys.
n = 122
4.01
(0.72)
3.73
(0.87)
0.28*
(0.89)
−0.05
(0.98)
−0.43
(0.81)
0.38*
(0.05, 0.71)
3.82
(0.86)
3.66
(0.85)
0.16
(−0.15, 0.47)
PACIC goal set.
n = 120
3.03
(0.97)
2.97
(1.00)
0.06
(0.97)
0.17
(1.00)
−0.21
(0.93)
0.39*
(0.02, 0.75)
3.04
(1.02)
2.95
(0.98)
0.09
(−0.27, 0.46)
PACIC prob. sol.
n = 121
3.42
(1.22)
3.48
(1.20)
0.05
(1.05)
0.40
(0.94)
−0.17
(1.07)
0.57*
(0.17, 0.95)
3.65
(1.08)
3.34
(1.26)
0.31
(−0.13, 0.74)
PACIC foll.-up.
n = 113
2.63
(1.00)
2.54
(1.05)
−0.09
(0.94)
0.05
(1.16)
−0.18
(0.79)
0.23
(−0.15, 0.60)
2.76
(1.20)
2.42
(0.97)
0.34
(−0.07, 0.74)
CI = 95% confidence interval; control = patients of the original control group; DBP = diastolic blood pressure; intervention = patients of the original intervention group; LDL =
low density lipoprotein-cholesterol; PACIC = Patient Assessment of Care for Chronic Conditions; PACIC pat. act = PACIC-subscale patient activation; PACIC del. sys = PACIC
subscale delivery system design; PACIC goal set = PACIC subscale goal setting; PACIC prob. sol = PACIC subscale problem solving; PACIC follow.-up = PACIC subscale fol-
low-up; SBP = systolic blood pressure; SD = standard deviation; T0 = baseline CARAT study 2010; T2 = follow-up 2014
* p <0.05
† CI of t-test; since LDL is not normally distributed significance test was performed by means of the two-sample Wilcoxon rank-sum (Mann-Whitney) test, where p = 0.0763.
Table 3: Changes in clinical parameters and PACIC Score according to treatment with the Chronic Care Model.
T2
working with
CCM
mean (SD)
T2
working without
CCM
mean (SD)
T2 with CCM –
T2 without CCM
mean (CI)
Difference
T2−T0 with CCM
mean (SD)
Difference
T2−T0 without CCM
mean (SD)
(Difference
T2−T0 with CCM) − (Differ-
ence T2−T0 without CCM)
mean (CI)
HbA1c (%)
n = 155
7.40
(1.33)
7.73
(1.29)
−0.33*
(−0.74, 0.08)†
−0.28
(1.41)
−0.05
(1.69)
−0.23
(−0.73, 0.26)
SBP (mm Hg)
n = 156
137.24
(19.99)
136.61
(15.91)
0.63
(−5.05, 6.30)
−3.77
(22.65)
−3.16
(19.67)
−0.61
(−7.30, 6.08)
DBP (mm Hg)
n = 156
77.48
(8.88)
76.89
(9.62)
0.58
(−2.36, 3.53)
−4.86
(12.16)
−4.19
(12.00)
−0.67
(−4.50, 3.16)
LDL (mmol/l)
n = 147
2.52
(0.88)
2.53
(1.07)
−0.01
(−0.33, 0.31)
0.07
(1.05)
−0.16
(1.05)
0.23
(−0.12, 0.57)
PACIC Sum
n = 110
3.16
(0.89)
3.23
(0.83)
−0.06
(−0.38, 0.27)
0.06
(0.73)
−0.22
(0.76)
0.28
(0.01, 0.57)
PACIC pat. act.
n = 122
3.68
(1.07)
3.81
(1.03)
−0.13
(−0.51, 0.24)
−0.04
(1.07)
−0.25
(0.92)
0.22
(−0.15, 0.59)
PACIC del. syst.
n = 122
3.71
(0.78)
3.73
(0.91)
−0.03
(−0.33, 0.28)
−0.16
(0.92)
−0.37
(0.87)
0.21
(−0.12, 0.54)
PACIC goal set.
n = 120
2.96
(1.05)
3.00
(0.96)
−0.04
(−0.40, 0.32)
0.14
(0.96)
−0.2
(0.96)
0.34
(−0.02, 0.70)
PACIC prob. sol.
n = 121
3.41
(1.15)
3.50
(1.23)
−0.09
(−0.53, 0.34)
0.27
(1.02)
−0.10
(1.06)
0.37
(−0.02, 0.76)
PACIC foll.-up.
n = 113
2.59
(1.12)
2.52
(1.04)
0.07
(−0.33, 0.47)
−0.03
(1.05)
−0.14
(0.87)
0.11
(−0.26, 0.48)
CCM = Chronic Care Model; CI = 95% confidence interval; control = patients of the original control group; DBP = diastolic blood pressure; intervention = patients of the original
intervention group; LDL = low density lipoprotein-cholesterol; PACIC = Patient Assessment of Care for Chronic Conditions; PACIC pat. act = PACIC-subscale patient activation;
PACIC del. sys = PACIC subscale delivery system design; PACIC goal set = PACIC subscale goal setting; PACIC prob. sol = PACIC subscale problem solving; PACIC follow.-
up = PACIC subscale follow-up; SBP = systolic blood pressure; SD = standard deviation; T0 = baseline CARAT study 2010; T2 = follow-up 2014
* p <0.05
† CI of t-test; since Hba1c is not normally distributed significance testing was performed by means of the two-sample Wilcoxon rank-sum (Mann-Whitney) test, where p =
0.0246.
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PACIC
The PACIC sum score improved significantly in practices
originally randomied to the intervention group compared
with the control group (intervention T2−T0 mean 0.16, SD
0.72 vs control T2−T0 mean −0.27, SD 0.73; DF 108, p =
0.003) (table 2). PACIC sum score did not differ between
practices currently still working with CCM and practices
working with the traditional treatment concept: CCM mean
0.06, SD 0.73 vs non-CCM mean −0.22, SD 0.76; p =
0.057 (table 3). These positive findings were confirmed
in three of the five PACIC subscales according to original
randomisation: delivery system design (intervention
T2−T0 mean −0.05, SD 0.98 vs control T2−T0 mean
−0.43, SD 0.81; DF 115, p = 0.024), goal setting (interven-
tion T2−T0 mean 0.17, SD 1.00 vs control T2−T0 mean
−0.21, SD 0.93; DF 110, p = 0.037) and problem solving
(intervention T2−T0 mean 0.40, SD 0.94 vs control T2−T0
mean −0.17, SD 1.07; DF 110, p = 0.005) (table 2). A trend
was found in favour of CCM practices in the subscales
goal setting (CCM T2−T0 mean 0.14, SD 0.96 vs no CCM
T2−T0 mean −0.2, SD 0.96; DF 110, p = 0.07) and prob-
lem solving (CCM T2−T0 mean 0.27, SD 1.02 vs no CCM
T0−T2 mean −0.10, SD 1.06; DF 110, p = 0.067) (table 3).
For the subscale delivery system design, a significant im-
provement could be shown (T0 mean 4.01, SD 0.72 vs T2
mean 3.73, SD 0.87; DF 116, p = 0.004). For patient ac-
tivation a trend in favour of the follow-up was found (T0
mean 3.94, SD 1.05 vs T2 mean 3.78, SD 1.05; DF 114, p
= 0.057) (table 2).
Discussion
Three years after the completion of the randomised con-
trolled CARAT trial, which assessed the effect of imple-
menting the CCM via involvement of a trained practice
nurse in the care for type 2 diabetes patients, approximate-
ly 40% of PCPs that participated in the follow up contin-
ued using the novel treatment model. PCPs originally ran-
domised to the intervention group of the CARAT study
were significantly more likely to be still using the CCM.
The main reasons for discontinuation were organisation-
al and financial aspects, and the general practitioner not
wanting to transfer treatment responsibility. HbA1c and
PACIC changes over the long term showed significantly
positive effects in favour of PCPs originally randomised
to the intervention group and PCPs continuing to treat pa-
tients according to the CCM.
Feasibility and benefit of the CCM in PCP
The CARAT trial has already shown that the implementa-
tion of the CCM, via a specially trained practice nurse ex-
hibiting the central role in the treatment of diabetic patients
in Swiss PCP, is possible and feasible [4, 6]. The current
long-term follow up confirmed these findings. The treat-
ment concept over 4 years of observation was, however,
sustained by less than half of the PCPs. This number is
possibly even overestimated owing to selection bias, when
considering that the six PCPs that refused participation in
the follow up possibly also did not continue treating pa-
tients according to CCM. PCPs originally randomised to
the intervention group were more likely to continue work-
ing with the CCM. This finding can be explained by fol-
lowing considerations: PCPs of the former intervention
group had, unlike the former control group, participated
in two interactive workshops during the CARAT trial, be-
sides training of the practice nurses. In these workshops,
the general practitioners too were trained in the concepts
of the CCM. These workshops also offered recurring op-
portunities to discuss experiences with and organisational
barriers to implementing the CCM with other teams, and
solutions were jointly developed. The results of the current
follow up suggest that training the entire team involved in
patient treatment increases understanding and implemen-
tation of the CCM, emphasising that this model requires
good collaboration between the patients, practice nurse and
general practitioner.
The steady increase in chronically ill people in an aging
population, paired with lack of appropriately prepared
medical staff, puts the continuous and structured treatment
of such patients in the spotlight, with a focus on increasing
the effectiveness and quality of patient-centred care, as
well as cost reduction [14–16]. The concept of task shifting
or skill mix as a solution for the shortage of general prac-
titioners has been investigated for a number of different
outcomes [17]. For financial aspects especially, such a re-
structuring of care has become attractive [18, 19]. A meta-
analysis by Martinez-Gonzales et al. concluded that care of
the chronically ill coordinated by specially trained nurses
is at least equivalent to a physician-dominated care struc-
ture [20]. Other studies have shown that task shifting might
be associated with an increased number and length of con-
sultations, although the frequency and quality of referrals,
examinations and prescriptions are comparable to physi-
cian-led care [21]. An additional meta-analysis confirmed
that nurse-led care achieves similar results to physician-led
care if it follows structured therapy protocols [22].
Barriers for implementing the CCM
This switch from physician- to nurse-led care presumes a
fundamental rethinking of the strongly enrooted and hi-
erarchical patient-physician and physician-practice nurse
relationship. In these new models, the practice nurse oc-
cupies a more central role in the treatment process, ac-
companied by an increased authority in the eyes of the pa-
tient and of the physician. This change of dogma implies
that the physician is capable of transferring the control
and authority of patient treatment. Our study showed that
this circumstance is a barrier to implementing the CCM
in the long term. Our study also showed that from the
patients’ perspective there are relevant barriers to the al-
tered patient-physician relationship and to the elements of
the CCM that are designed to promote personal respon-
sibility and patient self-management. Some patients pre-
fer seeing complete responsibility for their illness with the
physician, which renders the implementation of the CCM
nearly impossible. It seems, therefore, wise to implement
the concepts of the CCM as soon as possible into patient
treatment, in order to promote acceptance and associated
motivation.
In addition, current financial barriers hinder the long-term
implementation of the CCM. On the one hand, certain fi-
nancial investments in personnel, training and premises
have to be made. On the other hand, the remuneration of
specially trained practice nurses is not clearly settled in the
Swiss reimbursement system. Many hopes lie in the cur-
rently pending revision of the Swiss Standard Billing Rate
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for outpatient medical care in Switzerland (Tarmed), which
plans separate entries of services rendered by the practice
nurse.
As shown by numerous studies, the implementation of
the CCM can lead to improvement in chronic diseases
[23–25], but it has not been proven consistently in all stud-
ies. Possible explanations for this inconsistency are offered
by the implementation model from Grol and Wensing [26],
which groups existing barriers into seven levels: innova-
tion, specialist, patient, social, organisational, economic
and political. Our findings are in line with the recently pub-
lished systematic review from Busetto et al. [27], which
showed that most barriers occur on the organisational lev-
el, and could be overcome on the social level by means of
an increase in personnel and measures improving satisfac-
tion of employees.
Clinical parameters
Improvement of diabetes care constitutes a massive chal-
lenge in medicine. Stellefson et al. have shown improved
health of patients with diabetes in general practice with im-
plementation of the CCM elements [28]. The use of single
elements was shown not to be crucial, but rather the com-
bination of multiple elements. An improved cardiovascular
risk profile could not be achieved by consulting a specialist
in the treatment of type 2 diabetes patients [29]. The guide-
lines for the treatment of diabetic patients, including goal
HbA1c, have been modified on the basis of more recent
real-life data, taking into consideration that, depending on
age and comorbidities, too strict therapy leads to increased
morbidity and mortality [30–32].
The baseline HbA1c level of the CARAT population was
already relatively low (mean 7.74%) and in the current fol-
low up even lower (mean 7.58%). Therefore, among our
study population there was little room for improvement in
the HbA1c, without taking the risk of hypoglycaemia in-
to account. Nevertheless, the study showed a significantly
lower HbA1c in the original intervention group compared
with the original control group 4 years after the interven-
tion. In addition, HbA1c was significantly lower at the
time of the current follow up in practices that treat their
patients according to the CCM. These two findings under-
mine the sustained effect of such an intervention, in line
with other studies [24], and suggest that a treatment strate-
gy according to the CCM might even lead to a stronger ef-
fect in patients who have poorer diabetes control than our
population.
The finding that no relevant differences existed between
the intervention group and the control group with respect
to blood pressure and LDL-cholesterol can be possibly at-
tributed to selection bias, as only general practitioners who
have a corresponding interest in the subject were included
in the control group. A significant effect on diastolic blood
pressure only was found over time, not affected by ran-
domisation or use of CCM. The reason therefore probably
lies in the already low values (baseline mean 140.34/81.65
mm Hg, follow up mean136.90/77.16 mm Hg), which met
the suggested guideline values of <140/85 mm Hg [32] and
which hindered further improvements without risking of
side effects. Diverse other studies among patients with less
well controlled blood pressure have shown that, by means
of task shifting to a trained nurse, a significant effect on
systolic blood pressure can be achieved [33]. Also, the lack
of significant effects on LDL-cholesterol levels can be ex-
plained by the low baseline values (mean 2.58 mmol/l).
The improved PACIC scores, independent of original ran-
domisation or use of the CCM, are in line with findings
from a meta-analysis that showed that the care by a trained
nurse had positive effects on patient satisfaction and hospi-
talisation rate [34].
Strengths and limitations
Our data originated from a real-life setting in small, mostly
single-handed PCPs in Switzerland. The findings are there-
fore presumably applicable to most European countries
with small single-handed practices that are not experienced
in involving practice nurses as central agents in patient
care. Nevertheless, one has to take into consideration that
the extent of medical knowledge and clinical training of
practice nurses in Switzerland might not be comparable
to those from other European countries. The implementa-
tion of elements of the CCM has shown manifold posi-
tive effects on diverse chronic diseases, among them dia-
betes mellitus [35–39]. The benefit of its implementation
in small PCPs, which is the most common practice form in
most of Europe, has rarely been proven [4, 40]. Our study
confirmed that the implementation of the CCM is possible
with moderate efforts, including in the long term. The re-
turn rate of our follow up was representative at 64.03%.
A possible limitation of our study is that changes during
the period of observation, such as new clinical guidance
on diabetes care, or the implementation or development of
electronic patient records linked with diabetes monitoring
systems in the observed PCPs, may have influenced our
findings. Furthermore, lack of anonymity/blinding and re-
call bias are natural limitations of our study. According to
our inclusion criteria, only patients with a continuous re-
lation to their general practitioner were eligible to partici-
pate, meaning that patients who contacted the practice for
emergencies only or as a substitute practice were exclud-
ed. Therefore, a certain selection bias was introduced to
the study, since it was at the discretion of the participat-
ing team (practice nurse and general practitioner) to de-
cide whether the patients was considered a “regular cus-
tomer”. On the other hand, introducing this selection seems
clinically sensible since chronic care is the issue of in-
terest in our study. In addition, a certain selection bias
among the participating PCPs has to be considered, since
it seems likely that only general practitioners interested in
new treatment concepts were willing to participate in the
study. However, this renders our findings even more inter-
esting, in terms of barriers to continuing to work with these
innovative models in the long term mentioned by such a
motivated clientele.
Conclusions
Diabetes care according to the CCM, including the in-
volvement of trained practice nurses, is a reasonable tool
to improve care in the long term. CCM training of the
whole team is essential to overcome organisational chal-
lenges. Continual team education, technical decision sup-
port, and recognition of the importance of these new struc-
tures by healthcare policy makers might improve the long-
term clinical effect of the team approach.
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Appendix 1
Practice team questionnaire
The questionnaire is available as a separate file for down-
loading at: https://smw.ch/en/article/doi/smw.2017.14522/
Appendix 2
Patients questionnaire
The questionnaire is available as a separate file for down-
loading at https://smw.ch/en/article/doi/smw.2017.14522/
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